Thermo Fisher Scientific signs long-term, exclusive U.S. distributor agreement with Aesku.Group for IFA testing kits & instruments.

This agreement between Thermo Fisher Scientific and Aesku gives customers access to a comprehensive portfolio of autoimmune diagnostics and automated instrumentation, complimenting both the EliA™ autoimmune testing portfolio and Phadia™ laboratory instruments with Aesku IFA testing and Helios® HTC systems.

Thermo Fisher Scientific, the world leader in serving science, today announced an exclusive distribution agreement with Aesku.Group (Aesku), a leading provider of innovative diagnostic solutions, to market, sell, and support their portfolio of FDA-Cleared IFA products, automated instruments, and software in the United States. With this agreement, Thermo Fisher positions itself to offer laboratories a comprehensive suite of automated diagnostic systems and methodologies available in the U.S. market.

By expanding its immunology product portfolio of EliA autoimmune diagnostics, ImmunoCAP™ allergy diagnostics, and Phadia Laboratory Systems with complimentary reagents and systems from Aesku, Thermo Fisher will continue to meet the evolving needs of laboratories and healthcare professionals, enabling faster and more accurate diagnoses for patients.

"Our partnership with Aesku underscores our commitment to enabling our customers to make the world healthier by providing innovative solutions that help advance the detection and diagnosis of complex autoimmune diseases," stated Santhosh Nair, president of ImmunoDiagnostics, Thermo Fisher Scientific. “Aesku has pioneered innovative and efficient solutions that synergize seamlessly with our existing portfolio. We are excited about offering these solutions to our customers and the opportunity to positively impact more patient lives.”

Under the agreement, Thermo Fisher will engage in sales and marketing, as well as related activities, for Aesku products exclusively in the United States. Thermo Fisher will also provide installation, maintenance, and support services to customers in the United States. Aesku will continue to manufacture all products under the agreement.

Dr. Torsten Matthias, President and founder of Aesku said, “we are thrilled to enter this partnership with Thermo Fisher Scientific, a global diagnostics powerhouse, to bring our pioneering IFA solutions to the forefront of the U.S. market. Aesku's commitment to innovation in autoimmune diagnostics aligns seamlessly with Thermo Fisher's Mission of enabling customers to make the world healthier, cleaner and safer. Together, we are setting new benchmarks for accuracy and efficiency in autoimmunity testing, ensuring clinicians and patients receive the most advanced diagnostic capabilities available.”

For more information on Immunology solutions from Thermo Fisher Scientific, please visit https://www.thermofisher.com/phadia.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

About Aesku Group

AESKU.GROUP, based in Wendelsheim, Germany, is a research-focused supplier of innovative and efficient products and services for the early detection, diagnosis and prognosis of autoimmune diseases. Since its foundation in the year 2000 AESKU.DIAGNOSTICS has become a recognized name in the field of autoimmunity for launching over 150 different products together with uninterrupted services in more than 90 countries worldwide. Since then AESKU.Group simplifies the lab routine with accurate, robust and reliable tests, laying equal emphasis on all major disease sectors, the company has earned a solid reputation in autoimmune diagnostics.

GEIMPFT! Aber auch sicher? - AESKU.COVID19 CHECK Antikörper Einsendetest
 

AESKU.COVID19 CHECK

Produktinformation

Informationsbroschüre im PDF Format

AESKU.COVID19 CHECK

Kurzanleitung

Schnellanleitung im PDF Format

AESKU.COVID19 CHECK

Video Tutorial

Anwendungsvideo (Vimeo-Link)

AESKU.COVID19 CHECK

FAQ

Häufig gestellte Fragen 

Bei Fragen zu unserem AESKU.COVID19 CHECK Antikörper Einsendetest erreichen Sie unser Service-Team per E-Mail unter This email address is being protected from spambots. You need JavaScript enabled to view it. oder unter folgender Telefonnummer: 

+49 6734 9622 6666

(Montag bis Freitag, 9:00 - 17:00 Uhr)
Es handelt sich hierbei um eine Festnetzrufnummer. Für einen Anruf fallen die üblichen Kosten ins deutsche Festnetz an.
Wir bitten um Ihr Verständnis, dass bei erhöhtem Anrufaufkommen mit Wartezeiten zu rechnen ist. Für Produktanfragen den Verkauf betreffend, wenden Sie sich bitte an +49673496220.

 

Thermo Fisher Scientific signs long-term, exclusive U.S. distributor agreement with Aesku.Group for IFA testing kits & instruments.

This agreement between Thermo Fisher Scientific and Aesku gives customers access to a comprehensive portfolio of autoimmune diagnostics and automated instrumentation, complimenting both the EliA™ autoimmune testing portfolio and Phadia™ laboratory instruments with Aesku IFA testing and Helios® HTC systems. Read more...

 

EU Emblem mit Schriftzug Europäische Union

Development of an automatic rapid test system for blood diagnostics and immunoassays

AESKU. Group has received funding from the European Union's Fund for Region Growth 2014 – 2020 Program to develop an automated platform for the automation of Point-Of-Care (POC) Tests. Read more...

Challenges of the COVID-19 pandemic

 

Dear Valued Customers & Business Partners,

We want to reassure you that we remain committed to fulfilling your orders during the COVID-19 pandemic.

As we need to adapt to meet the challenges of the COVID-19 pandemic, we would like to inform you about our program maintaining our business processes, ensuring the health and safety of our customers, partners, and employees. We have introduced various internal working procedures in accordance with government guidelines and changes in working practices. In addition to the disinfection of our facilities and heightened fixed cleaning intervals, almost all employees, whose work allows it, are in the “home office.”

To further reduce possible virus transmission, AESKU decided to suspend all business trips of AESKU's employees immediately and to suspend our participation in exhibitions until further notice.

Trade fairs are generally canceled or postponed, because suppliers and service providers are unable to carry out their work as usual, or it is not permitted to enter or leave Germany from various countries.

Trade fair participation will be carefully evaluated based on future developments on a case-by-case basis. Stay tuned and see our latest news on WWW.AESKU.COM.

We believe that all these measures will help to flatten the curve of the COVID-19 and ensure the safety of our team and the functionality of our company. We are doing everything we can to provide you with the same high level of productivity and service in this particular situation. All our services remain fully available using the following platforms; you can be sure that our commitment to you remains unchanged.

Contact us:

www.aesku.com

This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel.: +49 6734/9622-0

AESKU.GROUP is determined to help you get over this difficult time and prepare adequately for the future. 

We thank you for your support and understanding.

Best regards and stay healthy,

Your Team at AESKU.GROUP

mbl bion logoAESKU.GROUP übernimmt MBL BION

Die AESKU.GROUP hat die Übernahme des Immunfluoreszenztest-Spezialisten MBL BION abgeschlossen und damit das Immunfluoreszenz-Produktportfolio und deren Produktion erweitert.

Open english Version | Zur deutschen Version wechseln